UP!

OREX $0.22

OREX target price
0.22
0
0
Orexigen Therapeutics, Inc.
Type
Public
Founded 2002 (2002)
Founder Eckard Weber
Headquarters La Jolla, California, U.S.
Website www.orexigen.com

Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in 2014. The launch of Contrave was conducted through a sales force of 900. Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-03-16 Lower Price Target Leerink Swann Market Perform $2.00 to $1.00
2016-03-16 Downgrade Piper Jaffray Overweight to Neutral $5.00 to $2.00
2016-03-16 Downgrade JMP Securities Outperform to Market Perform
2016-03-16 Downgrade Piper Jaffray Cos. Overweight to Neutral $5.00 to $2.00
2016-02-29 Lower Price Target JMP Securities $7.00 to $2.00
2016-02-29 Lower Price Target Piper Jaffray Overweight $11.00 to $5.00
2016-02-29 Downgrade JPMorgan Chase & Co. Overweight to Neutral
2016-02-29 Downgrade RBC Capital Outperform to Sector Perform $5.00 to $1.00
2016-02-29 Downgrade Royal Bank Of Canada Outperform to Sector Perform $5.00 to $1.00
2016-02-23 Downgrade Leerink Swann Outperform to Market Perform $4.50 to $2.00
2016-02-23 Downgrade Leerink Partner Outperform to Market Perform
2015-12-16 Downgrade WallachBeth Capital Buy to Hold
2015-12-12 Reiterated Rating Bank of America Sell
2015-12-12 Reiterated Rating Bank of America Corp. Sell
2015-12-11 Initiated Coverage Bank of America Underperform $2.00
2015-12-04 Downgrade Wells Fargo Outperform to Market Perform
2015-12-04 Downgrade Wells Fargo & Co. Outperform to Market Perform
2015-11-07 Reiterated Rating Leerink Swann Buy
2015-11-06 Reiterated Rating Leerink Swann Outperform $8.00 to $4.50
2015-11-06 Lower Price Target JMP Securities Market Outperform $7.00
2015-11-06 Lower Price Target RBC Capital Outperform $9.00 to $5.00
2015-10-06 Lower Price Target Piper Jaffray Overweight $21.00 to $11.00
2015-09-15 Reiterated Rating RBC Capital Outperform $14.00 to $9.00
2015-08-10 Reiterated Rating JPMorgan Chase & Co. Buy $8.00
2015-08-06 Reiterated Rating Piper Jaffray Buy $17.00 to $21.00
2015-05-14 Reiterated Rating RBC Capital Outperform $14.00
2015-05-14 Reiterated Rating Leerink Swann Outperform $11.00
2015-04-22 Set Price Target Bank of America Buy $13.00
2015-03-27 Boost Price Target RBC Capital Buy $10.00 to $14.00
2015-03-06 Reiterated Rating RBC Capital Buy
2015-03-04 Boost Price Target Leerink Swann Outperform $8.00 to $11.00
2015-03-03 Boost Price Target Piper Jaffray Overweight $16.00 to $26.00
2015-02-24 Reiterated Rating Leerink Swann Outperform $8.00
2015-01-22 Initiated Coverage RBC Capital Outperform $10.00
2015-01-02 Reiterated Rating Bank of America Buy $9.00 to $10.00
2014-11-10 Reiterated Rating Wells Fargo & Co. Outperform
2014-11-10 Reiterated Rating Wells Fargo Outperform
2014-09-11 Boost Price Target Wells Fargo & Co. $15.00
2014-09-11 Boost Price Target Wells Fargo $15.00
2014-09-04 Initiated Coverage Credit Suisse Outperform $10.00
2014-09-04 Initiated Coverage Credit Suisse Group AG Outperform $10.00
2014-04-24 Initiated Coverage Wells Fargo & Co. Outperform
2014-04-24 Initiated Coverage Wells Fargo Outperform
2014-01-10 Initiated WallachBeth Buy $9
2014-01-10 Initiated Coverage WallachBeth Capital Buy $9.00
2013-11-27 Reiterated Rating JPMorgan Chase & Co. Overweight to Positive $12.00
2013-11-26 Lower Price Target Credit Suisse Outperform $11.00 to $10.00
2013-10-04 Reiterated Rating Jefferies Group Hold $7.00
2013-10-03 Initiated Coverage Cowen and Company Outperform to Outperform $10.00
2011-09-21 Upgrade JMP Securities Mkt Perform to Mkt Outperform $5
2011-02-01 Downgrade JMP Securities Mkt Outperform to Mkt Perform
2011-02-01 Downgrade Canaccord Genuity Buy to Hold
2010-12-03 Downgrade Rodman & Renshaw Mkt Perform to Mkt Underperform
2010-02-02 Initiated Jefferies & Co Buy $12
2009-03-13 Reiterated Lazard Capital Mkts Buy $13 to $10
2008-04-03 Initiated Cowen & Co Outperform
2008-02-06 Initiated Lazard Capital Buy
2008-02-04 Reiterated Canaccord Adams Buy $29 to $32
2008-01-03 Initiated JP Morgan Overweight
2007-10-03 Upgrade JMP Securities Mkt Outperform to Strong Buy $26
2007-06-07 Initiated JP Morgan Overweight
2007-06-06 Initiated JMP Securities Mkt Outperform $26
2016-03-16 Lower Price Target Leerink Swann Market Perform $2.00 to $1.00
2016-03-16 Downgrade Piper Jaffray Overweight to Neutral $5.00 to $2.00
2016-03-16 Downgrade JMP Securities Outperform to Market Perform
2016-03-16 Downgrade Piper Jaffray Cos. Overweight to Neutral $5.00 to $2.00
2016-02-29 Lower Price Target JMP Securities $7.00 to $2.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In OREX 0 funds of 2207 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
DOMAIN PARTERS VII L P 2.42%  (2967415) AKAO / CADX / CLVS / ESPR / EVOK / OREX / RGDO / TNDM / ZGNX /
TURNER DANIEL K III 0.31%  (377958) OREX / TSPT /
DOVEY BRIAN H 0.11%  (129448) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / OTIC / RGDO / TNDM / VCYT / ZGNX /
DP VII ASSOCIATES LP 0.04%  (50643) AKAO / CADX / CLVS / ESPR / EVOK / OREX / TNDM / ZGNX /
SCHOEMAKER KATHLEEN K 0.04%  (50643) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
BLAIR JAMES C 0.04%  (50643) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
VITULLO NICOLE 0.04%  (50643) ACHN / AKAO / CADX / CLVS / CPXX / DRNA / DRTX / ESPR / EVOK / MRNS / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
TREU JESSE I 0.04%  (50643) ACHN / AKAO / ALDX / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
Halak Brian K 0.04%  (50643) ACHN / AKAO / ALIM / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / TNDM / VCYT / VNDA / ZGNX /
Hagan Joseph P Sr. VP, Corporate Development 0.01%  (13026) OREX / RGLS / ZSAN /
NARACHI MICHAEL President and CEO 0.01%  (8356) AMAG / CLDN / OREX /
Booth Mark D Chief Commercial Officer 0.01%  (8028) OREX /